Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

Becton, Dickinson (BDX) stock gains as the company boosts fiscal 2025 earnings outlook after better than expected Q3 results.

Becton Dickinson shares surged over 8% in premarket trading on Thursday after the medical technology company reported ...

Becton, Dickinson and Company (NYSE:BDX) is one of the top stocks that Grok recommended. On July 31, Becton, Dickinson and ...

Shares of Becton Dickinson & Co. rose 8.86% to $187.68 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.08% to 6,340.00 and Dow ...

Hello, and welcome to BD’s Third Fiscal Quarter 2025 Earnings Call. At the request of BD, today’s call is being recorded and ...

Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical ...

Becton Dickinson & Co. closed 29.80% below its 52-week high of $251.99, which the company reached on February 3rd.

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 ...

Becton Dickinson raised its forecast for annual profit on Thursday, after beating Wall Street estimates for third-quarter profit and sales on strong demand for its drug-delivery devices.

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider Becton Dickinson in a stock-and-cash transaction valued at $17.5 billion, ...

The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Chris DelOrefice ...